Arrowhead Pharmaceuticals: Important Catalysts And Some Challenges Ahead
Source: SeekingAlpha
2025-11-17 10:08:12 ET
Arrowhead Pharmaceuticals ( ARWR ) has a busy schedule in the next few weeks. The PDUFA date for plozasiran for the treatment of familiar chylomicronemia syndrome (‘FCS’) is tomorrow, fiscal Q4 2025 results are expected next week, and we should also see the preliminary results from the trials of ARO-INHBE and ARO-ALK7 in obese individuals between now and the JP Morgan Healthcare Conference in early January....
Read the full article on Seeking Alpha
For further details see:
Arrowhead Pharmaceuticals: Important Catalysts And Some Challenges Ahead
Sarepta Therapeutics Inc.
NASDAQ: SRPT
SRPT Trading
-1.75% G/L:
$16.67 Last:
898,612 Volume:
$17.47 Open:
SRPT Latest News
February 27, 2026 09:00:00 am
Sarepta Therapeutics Announces Call for Applications for the 9th Annual Route 79, The Duchenne Scholarship Program
SRPT Stock Data
$1,921,797,010
96,823,361
N/A
132
N/A
Biotechnology & Life Sciences
Healthcare
US
Cambridge
